Article Type
Case Report
Published
This report discusses silymarin in a patient with diabetes and grade II non-alcoholic steatohepatitis, confirming significant hepatoprotective effects as shown by the reduction of liver enzyme activities.
Drugs in Context Gastroenterology welcomes a broad range of article types including original research, study protocols and review articles.
In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.
Case Report
This report discusses silymarin in a patient with diabetes and grade II non-alcoholic steatohepatitis, confirming significant hepatoprotective effects as shown by the reduction of liver enzyme activities.
Case Report
This case report discusses a patient with tuberculosis who experienced drug-induced liver injury, and the initiation of treatment with silymarin resulted in a significant hepatoprotective effects as shown by decreased liver enzyme activity.
Case Report
This case report discusses daily treatment with silymarin and highlights moderate efficacy and a good safety profile in the management of non-alcoholic steatohepatitis (NASH) and liver function with no side-effects, supporting silymarin as a promising supplemental intervention that can normalize liver activity in non-alcoholic fatty liver disease and NASH.
Case Report
This case report focuses on a patient planning surgery due to lumbar stenosis who was recommended for silymarin treatment, as increased liver enzyme levels were incidentally
found during examination.
Case Report
This case report discusses personalized management of a patient with metabolic-associated fatty liver disease with advanced fibrosis and severe steatosis. The article examines impact of silymarin use, concomitant treatment with diet, exercise, insulin sensitizers and antifibrotic agents.